Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer

doi:10.3760/cma.j.cn371439-20230925-00039

Abstract

Abstract:

Targeted therapy for breast cancer can significantly improve the prognosis， quality of life and survival of breast cancer patients， but the emergence of primary or acquired drug resistance will eventually lead to disease progression， recurrence or metastasis. Tumor microenvironment （TME） is a complex environment for breast cancer cells to survive. Breast cancer cells and TME are currently known to be a functional whole， and the crosstalk between them plays a key role in breast cancer progression and resistance to targeted therapies. Therefore， clarifying TME abnormalities is important to reveal the underlying mechanisms of targeted therapy resistance and to develop therapeutic strategies against targeted therapy-resistant malignancies.

Key words: Breast neoplasms, Tumor microenvironment, Molecular targeted therapy, Drug resistance, neoplasm

Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.

References 31

[1]	Lei SY, Zheng RS, Zhang SW, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun (Lond), 2021, 41(11): 1183-1194. DOI: 10.1002/cac2.12207.
[2]	高晓敏, 郭旭, 王玲, 等. 肿瘤微环境调控乳腺癌HER2靶向药物耐药机制及逆转策略[J]. 中国癌症防治杂志, 2023, 15(5): 581-586. DOI: 10.3969/j.issn.1674-5671.2023.05.18.
[3]	Amer HT, Stein U, El Tayebi HM. The monocyte, a maestro in the tumor microenvironment (TME) of breast cancer[J]. Cancers (Basel), 2022, 14(21): 5460. DOI: 10.3390/cancers14215460.
[4]	Liu Y, Ji XM, Kang NN, et al. Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer[J]. Cell Death Dis, 2020, 11(11): 993. DOI: 10.1038/s41419-020-03161-x. pmid: 33214550
[5]	Qiao JH, Chen YB, Mi YJ, et al. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE[J]. Biochem Pharmacol, 2020, 180: 114126. DOI: 10.1016/ j.bcp.2020.114126.
[6]	Mehta AK, Cheney EM, Hartl CA, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer[J]. Nat Cancer, 2021, 2(1): 66-82. DOI: 10.1038/s43018-020-00148-7.
[7]	You D, Kim H, Jeong Y, et al. Tumorigenicity of EGFR- and/or HER2-positive breast cancers is mediated by recruitment of tumor-associated macrophages[J]. Int J Mol Sci, 2023, 24(2): 1443. DOI: 10.3390/ijms24021443.
[8]	Ahmed S, Mohamed HT, El-Husseiny N, et al. IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src/STAT3/ERK1/2-mediated EGFR signaling[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868(6): 118995. DOI: 10.1016/j.bbamcr.2021.118995.
[9]	Hu XC, Liu YW, Zhang XS, et al. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer[J]. Neoplasia, 2020, 22(11): 539-553. DOI: 10.1016/j.neo.2020.08.007. pmid: 32966956
[10]	Salemme V, Centonze G, Avalle L, et al. The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity[J]. Front Oncol, 2023, 13: 37265795. DOI: 10.3389/fonc.2023.1170264.
[11]	Liu X, Lu Y, Huang J, et al. CD16⁺fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition[J]. Cancer Cell, 2022, 40(11): 1341-1357. DOI: 10.1016/j.ccell.2022.10.015.
[12]	Du RX, Zhang XM, Lu XY, et al. PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity[J]. Drug Resist Updat, 2023, 68: 100947. DOI: 10.1016/j.drup.2023.100947.
[13]	Watson SS, Dane M, Chin K, et al. Microenvironment-mediated mechanisms of resistance to HER2 inhibitors differ between HER2⁺ breast cancer subtypes[J]. Cell Syst, 2018, 6(3): 329-342.e6. DOI: 10.1016/j.cels.2018.02.001.
[14]	Novotny CJ, Pollari S, Park JH, et al. Overcoming resistance to HER2 inhibitors through state-specific kinase binding[J]. Nat Chem Biol, 2016, 12(11): 923-930. DOI: 10.1038/nchembio.2171. pmid: 27595329
[15]	Fernández-Nogueira P, Mancino M, Fuster G, et al. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation[J]. Clin Cancer Res, 2020, 26(6): 1432-1448. DOI: 10.1158/1078-0432.CCR-19-0353. pmid: 31699826
[16]	Zou YT, Zheng SQ, Xie XH, et al. N⁶-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer[J]. Nat Commun, 2022, 13(1): 2672. DOI: 10.1038/s41467-022-30217-7. pmid: 35562334
[17]	Zervantonakis IK, Poskus MD, Scott AL, et al. Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of mTOR and antiapoptotic pathways[J]. Proc Natl Acad Sci U S A, 2020, 117(28): 16500-16508. DOI: 10.1073/pnas.2000648117.
[18]	Elshazly AM, Gewirtz DA. An overview of resistance to human epidermal growth factor receptor 2 (HER2) targeted therapies in breast cancer[J]. Cancer Drug Resist, 2022, 5(2): 472-486. DOI: 10.20517/cdr.2022.09. pmid: 35800378
[19]	Zazo S, González-Alonso P, Martín-Aparicio E, et al. Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer[J]. Mol Cancer Ther, 2020, 19(8): 1696-1707. DOI: 10.1158/1535-7163.MCT-19-1172. pmid: 32404410
[20]	Zheng GX, Guo ZY, Li WM, et al. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab[J]. Signal Transduct Target Ther, 2021, 6(1): 236. DOI: 10.1038/s41392-021-00629-w.
[21]	曹长青. 增强ADCC效应提高曲妥珠单抗治疗HER2阳性乳腺癌疗效的相关研究[D]. 西安: 中国人民解放军空军军医大学, 2023. DOI: 10.27002/d.cnki.gsjyu.2023.000305.
[22]	Liu SY, Li SQ, Wang BL, et al. Cooperative effect of oncogenic Met and PIK3CA in an HGF-dominant environment in breast cancer[J]. Mol Cancer Ther, 2019, 18(2): 399-412. DOI: 10. 1158/1535-7163.MCT-18-0710.
[23]	Singh S, Lamichhane A, Rafsanjani Nejad P, et al. Therapeutic targeting of stromal-tumor HGF-MET signaling in an organotypic triple-negative breast tumor model[J]. Mol Cancer Res, 2022, 20(7): 1166-1177. DOI: 10.1158/1541-7786.MCR-21-0317.
[24]	Mortezaee K, Majidpoor J. The impact of hypoxia on extracellular vesicle secretome profile of cancer[J]. Med Oncol, 2023, 40(5): 128. DOI: 10.1007/s12032-023-01995-x. pmid: 36964452
[25]	Wu XL, Ren Y, Yao R, et al. Circular RNA circ-MMP11 contributes to lapatinib resistance of breast cancer cells by regulating the miR-153-3p/ANLN axis[J]. Front Oncol, 2021, 11: 639961. DOI: 10.3389/fonc.2021.639961.
[26]	Zhang HL, Yan CX, Wang YH. Exosome-mediated transfer of circHIPK3 promotes trastuzumab chemoresistance in breast cancer[J]. J Drug Target, 2021, 29(9): 1004-1015. DOI: 10.1080/1061186X.2021.1906882.
[27]	Chen MK, Du Y, Sun L, et al. H₂O₂ induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism[J]. J Biol Chem, 2019, 294(21): 8516-8528. DOI: 10.1074/jbc.RA118.005953.
[28]	Chu YY, Yam C, Chen MK, et al. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer[J]. Am J Cancer Res, 2020, 10(2): 648-661.
[29]	Henke E, Nandigama R, Ergün S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy[J]. Front Mol Biosci, 2019, 6: 160. DOI: 10.3389/fmolb.2019.00160. pmid: 32118030
[30]	Neophytou C, Boutsikos P, Papageorgis P. Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis[J]. Front Oncol, 2018, 8: 31. DOI: 10.3389/fonc.2018.00031. pmid: 29520340
[31]	Hanker AB, Estrada MV, Bianchini G, et al. Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2⁺ breast cancer[J]. Cancer Res, 2017, 77(12): 3280-3292. DOI: 10.1158/0008-5472.CAN-16-2808.